Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OSTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| LmddA-LLO-chHER2 Fusion Protein-secretin | Bone Cancer | Phase 2 · NCT04974008 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OSTX holds $205,035 in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 0.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OSTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Shalom Auerbach Former 10% Owner |
Insider | 2,677,570 | 5.80% | 2025-07-29 |
| Paul A. Romness President and CEO, Director · +2.50M options |
Insider | 2,473,000 | 5.36% | 2026-01-22 |
| Vanguard Capital Management LLC | Institution (13F) | 777,651 | 1.69% | 2026-06-30 |
| Theodore F. Search Director · +230,000 options |
Insider | 455,835 | 0.99% | 2026-01-22 |
| John Ciccio Director · +230,000 options |
Insider | 455,835 | 0.99% | 2026-01-22 |
| CM Management, LLC | Institution (13F) | 400,000 | 0.87% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 301,794 | 0.65% | 2026-06-30 |
| Howard Financial Services, Ltd. | Institution (13F) | 248,001 | 0.54% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 242,479 | 0.53% | 2026-06-30 |
| Colin Goddard Director · +400,000 options |
Insider | 225,179 | 0.49% | 2024-12-31 |
| Robert Petit Officer · +600,000 options |
Insider | 200,000 | 0.43% | 2026-01-22 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 174,132 | 0.38% | 2026-06-30 |
Share count 46,125,825 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-01-22 filed 2026-02-13 |
Search Theodore F. |
Option award (A) | 50,000 | – | – |
| 2026-01-22 filed 2026-02-13 |
Ciccio John |
Option award (A) | 50,000 | – | – |
| 2026-01-22 filed 2026-02-13 |
Acevedo Christopher P. |
Option award (A) | 100,000 | – | – |
| 2026-01-22 filed 2026-02-13 |
Romness Paul A. |
Option award (A) | 1,000,000 | – | – |
| 2026-01-22 filed 2026-02-13 |
Galzahr Karim |
Option award (A) | 50,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OSTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →